| Literature DB >> 32019292 |
Eun Sang Yu1, Min Ji Jeon1, Ka-Won Kang2, Byung-Hyun Lee2, Eun Joo Kang1, Yong Park2, Se Ryeon Lee3, Hwa Jung Sung3, Chul Won Choi1, Byung Soo Kim2, Dae Sik Kim1.
Abstract
BACKGROUND/AIMS: Various preoperative screening tests, such as platelet count, prothrombin time, activated partial thromboplastin time, and bleeding time, have been widely used to evaluate the risk of bleeding during surgery. Use of platelet function analyzer (PFA)-100/200 for assessing platelet function instead of bleeding time is increasing. However, its role in predicting the perioperative risk of bleeding remains controversial.Entities:
Keywords: Bleeding; Platelet function analyzer; Screening test; Surgery
Mesh:
Year: 2020 PMID: 32019292 PMCID: PMC7487293 DOI: 10.3904/kjim.2019.112
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Baseline characteristics of included patients
| Characteristic | Total (n = 703) | PFA closure time | ||
|---|---|---|---|---|
| Normal (n = 480) | Prolongation (n = 223) | |||
| Age, yr | 60 (18–95) | 56 (18–94) | 61 (18–95) | < 0.001 |
| Sex, male/female | 360/343 | 260/220 | 100/123 | 0.021 |
| Body mass index, kg/m2 | 23.6 (14.1–41.9) | 23.4 (14.1–41.9) | 24.1 (15.2–35.5) | 0.189 |
| Underlying disease, % | ||||
| Hepatic disease | 67 (9.5) | 44 (9.2) | 23 (10.3) | 0.630 |
| Hypertension | 201 (28.6) | 121 (25.2) | 80 (35.9) | 0.004 |
| Cardiac disease | 61 (8.7) | 27 (5.6) | 34 (15.2) | < 0.001 |
| Pulmonary disease | 26 (3.7) | 17 (3.5) | 9 (4.0) | 0.747 |
| Cerebrovascular disease | 49 (7.0) | 29 (6.0) | 20 (9.0) | 0.156 |
| Malignancy | 83 (11.8) | 62 (12.9) | 21 (9.4) | 0.181 |
| Diabetes mellitus | 91 (12.9) | 55 (11.5) | 36 (16.1) | 0.085 |
| Thyroid disease | 50 (7.1) | 30 (6.2) | 20 (9.0) | 0.192 |
| Chronic kidney disease | 30 (4.3) | 19 (4.0) | 11 (4.9) | 0.552 |
| Anticoagulant, % | < 0.001 | |||
| Aspirin | 60 (8.5) | 24 (5.0) | 36 (16.1) | |
| Other antiplatelet | 41 (5.8) | 26 (5.4) | 15 (6.7) | |
| Aspirin + other | 14 (2.0) | 5 (1.0) | 9 (4.0) | |
| NSAID, % | 252 (35.8) | 134 (27.9) | 118 (52.9) | < 0.001 |
Values are presented as median (range) or number (%).
PFA, platelet function analyzer; NSAID, nonsteroidal anti-inflammatory drug.
Baseline laboratory findings
| Characteristic | Total (n = 703) | PFA closure time | ||
|---|---|---|---|---|
| Normal (n = 480) | Prolongation (n = 223) | |||
| Hemoglobin, g/L | 0.002 | |||
| ≥ 120 | 470 (66.9) | 339 (70.6) | 131 (58.7) | |
| < 120 | 233 (33.1) | 141 (29.4) | 92 (41.3) | 0.010 |
| Hematocrit, % | ||||
| ≥ 35 | 513 (73.0) | 366 (76.2) | 147 (65.9) | |
| < 35 | 154 (21.9) | 90 (18.8) | 64 (28.7) | |
| WBC count, /L | 0.766 | |||
| 4.5–11 × 109 | 483 (68.7) | 330 (68.8) | 153 (68.6) | |
| < 4.5 × 109 | 34 (4.8) | 25 (5.2) | 9 (4.0) | |
| ≥ 11 × 109 | 186 (26.5) | 125 (26.0) | 61 (27.4) | |
| PLT count, /L | 0.837 | |||
| ≥ 150 × 109 | 636 (90.5) | 435 (90.6) | 201 (90.1) | |
| < 150 × 109 | 67 (9.5) | 45 (9.4) | 22 (9.9) | 0.324 |
| PT | ||||
| Normal | 692 (98.4) | 474 (98.8) | 218 (97.8) | |
| Prolongation | 11 (1.6) | 6 (1.2) | 5 (2.2) | 0.646 |
| aPTT | ||||
| Normal | 660 (94.3) | 452 (94.6) | 208 (93.7) | |
| Prolongation | 40 (5.7) | 26 (5.4) | 14 (6.3) | |
| Albumin | 0.681 | |||
| Normal | 619 (88.1) | 421 (87.7) | 198 (88.8) | |
| Abnormal | 84 (11.9) | 59 (12.3) | 25 (11.2) | |
| Bilirubin | 0.768 | |||
| Normal | 637 (90.6) | 436 (90.8) | 201 (90.1) | |
| Abnormal | 66 (9.4) | 44 (9.2) | 22 (9.9) | |
| Creatinine | 0.319 | |||
| Normal | 673 (95.7) | 462 (96.2) | 211 (94.6) | |
| Abnormal | 30 (4.3) | 18 (3.8) | 12 (5.4) | |
Values are presented as number (%).
PFA, platelet function analyzer; WBC, white blood cell; PLT, platelet; PT, prothrombin time; aPTT, activated partial thromboplastin time.
Types of surgery assessed in the study
| Characteristic | Total (n = 703) | PFA closure time | ||
|---|---|---|---|---|
| Normal (n = 480) | Prolongation (n = 223) | |||
| Severity of surgery | 0.757 | |||
| Major[ | 444 (63.2) | 305 (63.5) | 139 (62.3) | |
| Minor[ | 259 (36.8) | 175 (36.5) | 84 (37.7) | |
| Category of surgery | 0.939 | |||
| Orthopedic surgery | 221 (31.4) | 153 (31.9) | 68 (30.5) | |
| Abdominal surgery | 227 (32.3) | 155 (32.3) | 72 (32.3) | |
| Neurosurgery | 68 (9.7) | 41 (8.5) | 27 (12.1) | |
| Thoracic surgery | 44 (6.3) | 34 (7.1) | 10 (4.5) | |
| Plastic surgery | 26 (3.7) | 18 (3.8) | 8 (3.6) | |
| Gynecological surgery | 25 (3.6) | 16 (3.3) | 9 (4.0) | |
| Otolaryngologic surgery | 17 (2.4) | 12 (2.5) | 5 (2.2) | |
| Urologic surgery | 13 (1.8) | 9 (1.9) | 4 (1.8) | |
| Cardiovascular surgery | 11 (1.6) | 7 (1.5) | 4 (1.8) | |
| Ophthalmic surgery | 4 (0.6) | 2 (0.4) | 2 (0.9) | |
| Breast surgery | 3 (0.4) | 2 (0.4) | 1 (0.4) | |
| Others[ | 44 (6.3) | 31 (6.5) | 13 (5.8) | |
Values are presented as number (%).
PFA, platelet function analyzer.
Major surgery: any procedure in which a body cavity was entered, a mesenchymal barrier was crossed, a facial plane was opened, an organ was removed, or normal anatomy was altered.
Minor surgery: any operative procedure in which only the skin, mucous membranes, or superficial connective tissue were manipulated, such as gastroscopy, colonoscopy, and similar procedures.
Others include biopsy, simple incision & drainage, catheter insertion, and endoscopic procedure.
Factors affecting the results of PFA closure time
| Characteristic | COL/EPI | COL/ADP | ||||
|---|---|---|---|---|---|---|
| Number | Closure time | Number | Closure time | |||
| Anti-platelet drug | ||||||
| No use | 587 | 154 (35–300) | < 0.001 | 153 | 108 (43–300) | 0.391 |
| Aspirin | 59 | 250 (83–300) | 30 | 118 (46–300) | ||
| Other antiplatelet | 40 | 177 (86–300) | 18 | 105 (81–300) | ||
| Combination | 14 | 265 (109–300) | 8 | 114 (60–300) | ||
| NSAID | ||||||
| No | 449 | 147 (35–300) | < 0.001 | 111 | 109 (43–300) | 0.249 |
| Yes | 251 | 215 (50–300) | 98 | 107 (46–300) | ||
| Hemoglobin, g/L | ||||||
| ≥ 120 | 469 | 153 (56–300) | 0.027 | 126 | 103 (43–300) | < 0.001 |
| < 120 | 231 | 181 (35–300) | 83 | 124 (60–300) | ||
| Hematocrit, % | ||||||
| ≥ 35 | 512 | 157 (56–300) | 0.039 | 141 | 103 (43–300) | < 0.001 |
| < 35 | 188 | 191 (35–300) | 68 | 131 (60–300) | ||
| Platelet count, /L | ||||||
| ≥ 150 × 109 | 633 | 161 (35–300) | 0.542 | 191 | 108 (43–300) | 0.017 |
| < 150 × 109 | 67 | 167 (71–300) | 18 | 116 (89–300) | ||
| Blood collection time[ | ||||||
| Dawn | 87 | 169 (50–300) | 0.004 | 36 | 100 (60–300) | 0.766 |
| Morning | 160 | 148 (35–300) | 58 | 107 (45–300) | ||
| Afternoon | 303 | 157 (56–300) | 83 | 109 (46–300) | ||
| Night | 150 | 186 (81–300) | 35 | 110 (43–300) | ||
| Blood group | ||||||
| A | 237 | 163 (71–300) | 0.916 | 71 | 100 (46–300) | 0.122 |
| B | 192 | 156 (35–300) | 53 | 110 (58–300) | ||
| AB | 80 | 152 (68–300) | 24 | 99 (45–300) | ||
| O | 191 | 169 (50–300) | 61 | 115 (43–300) | ||
Values are presented as median (range). Prothrombin time and activated partial thromboplastin time were excluded because the number of abnormal results was too small.
PFA, platelet function analyzer; COL/EPI, collagen/epinephrine; COL/ADP, collagen/adenosine diphosphate; NSAID, nonsteroidal anti-inflammatory drug.
Dawn, 0:00–6:00; Morning, 6:00–12:00; Afternoon, 12:00–18:00; Night, 18:00–24:00.
Postoperative bleeding outcomes according to PFA test results
| Characteristic | PFA closure time (COL/EPI) | ||
|---|---|---|---|
| Normal | Prolongation | ||
| Intra-operation | |||
| Blood loss ≥ 300 mL | 72 (14.3) | 40 (20.1) | 0.058 |
| Volume of bleeding | 600 (50–5,000) | 500 (120–6,500) | 0.569 |
| RBC transfusion | 76 (15.1) | 40 (20.1) | 0.106 |
| Within 72 hours after surgery | |||
| Postoperative Hb reduction ≥ 30 g/L | 112 (22.2) | 51 (25.6) | 0.335 |
| Postoperative RBC transfusion | 118 (23.4) | 63 (31.7) | 0.024 |
| Hospitalization days | 11 (1–125) | 11 (1–159) | 0.693 |
Values are presented as number (%) or median (range).
PFA, platelet function analyzer; COL/EPI, collagen/epinephrine; RBC, red blood cell; Hb, hemoglobin.
Results of logistic regression analysis for intra-operation bleeding loss
| Factor | Univariate analysis | Multivariate analysis | |
|---|---|---|---|
| HR (95% CI) | |||
| Sex | 0.780 | ||
| Age | < 0.001 | 1.02 (1.01–1.03) | 0.002 |
| Severity of surgery | < 0.001 | 3.56 (2.04–6.22) | < 0.001 |
| BMI | 0.236 | ||
| Use of anticoagulant | < 0.001 | ||
| Use of NSAID | 0.126 | ||
| Hemoglobin | < 0.001 | ||
| WBC count | 0.483 | ||
| PLT | 0.064 | ||
| PT | 0.076 | ||
| aPTT | < 0.001 | 2.81 (1.31–6.01) | 0.008 |
| Albumin | < 0.001 | 4.29 (2.49–7.40) | < 0.001 |
| Bilirubin | 0.376 | ||
| Creatinine | 0.107 | ||
| COL/EPI | 0.059 | 1.55 (0.97–2.47) | 0.068 |
| COL/ADP | 0.996 | ||
HR, hazard ratio; CI, confidence interval; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug; WBC, white blood cell; PLT, platelet; PT, prothrombin time; aPTT, activated partial thromboplastin time; COL/EPI, collagen/epinephrine; COL/ADP, collagen/adenosine diphosphate.